Time-course changes in blood glucose (BG; A), C peptide (B), and non-esterified fatty acid (NEFA; C) levels. Time-course changes in blood glucose (BG;

Slides:

Advertisements

Similar presentations

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

Advertisements

The 75 g glucose loading test.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type 2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.

Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

Changes in BG levels from 60 min (immediately before the first stair climbing–descending exercise (ST-EX)) to 180 min postmeal. Changes in BG levels from.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Suggested pathway for discussions between healthcare professionals and people with diabetes intending to fast during Ramadan. CBG, capillary blood glucose; DVLA,

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Localization of putative cholesterol-binding motifs in the homology model of human glucose transporter 1 (GLUT1) protein. Localization of putative cholesterol-binding.

Daily changes in ED use compared to baseline utilization in October and November 2012 for patients with diabetes in New York City evacuation zone level.

Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.

Plasma adiponectin levels by race/ethnicity (1A) and gender (1B) among study participants who developed prediabetes/diabetes (Progressors, P) compared.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

Metabolic syndrome—participants with only three components—expected and observed frequencies by age. Metabolic syndrome—participants with only three components—expected.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Exercise PA in MET-hours/week versus total leisure sedentary behavior in hours/day and incident type 2 diabetes mellitus from 2000 to Exercise PA.

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Mean and interquartile glucose values for (A) random blood glucose, (B) fastingplasma glucose, (C) HbA1c, (D) 1-hour OGTT, (E) 2-hour OGTT and (F)triglycerides.

Age-adjusted and sex-adjusted prevalence of diabetes of Asian immigrants and whites in California from 2003 to Age-adjusted and sex-adjusted prevalence.

Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

The results of the influenza vaccination measured by hemagglutination inhibition assay (HIA) among healthy elderly and elderly patients with type 2 diabetes.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Experimental protocol for days 2, 3 and 4.

(A) Urinary L-FABP (ULFABP) values in eight participants who had more than 5 µg/g creatinine (Cr) at the start of the study, at baseline and after treatment.

Whole-body protein kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body protein kinetics in C and T2D-O during postabsorptive and.

Difference in the prevalence of sarcopenia and its components (low muscle strength and low muscle mass) between NDR, NPDR and PDR. NDR, no diabetic retinopathy;

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

(A) Glucose values (mean +SEM) during continuous glucose monitoring while consuming whey protein (solid lines and filled circles) or placebo (broken lines.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Interaction of updated mean serial HbA1c and serum triglyceride levels with sensory peripheral neuropathy over 7 years in 151 type 2 diabetic participants.

Mean decline in grip strength with aging by baseline quartile of fasting plasma glucose (FPG). Mean decline in grip strength with aging by baseline quartile.

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Continuous associations

Receiver-operating characteristic curves showing the performance of the diabetes risk score in predicting diabetes in the United Arab Emirates (UAE) citizens.

Mean decline in grip strength with aging is shown for participants categorized by baseline quartile of 2 h glucose (2HG). Mean decline in grip strength.

Estimated glucose delta values (mmol/L) after glucagon injection (5 µg/kg) in octreotide-treated rats. Estimated glucose delta values (mmol/L) after glucagon.

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Comorbid conditions and concomitant medications.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

(A) Changes in BG level during REST, ST-EX and BI-EX trials in the combined (ALL) group. * and ** indicate the presence of significant differences (p

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

(A) Scatter plot showing the correlation between fasting second void UCPCR and fasting serum C peptide during a 75 g OGTT (rs 0.675, p

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

Presentation transcript:

Time-course changes in blood glucose (BG; A), C peptide (B), and non-esterified fatty acid (NEFA; C) levels. Time-course changes in blood glucose (BG; A), C peptide (B), and non-esterified fatty acid (NEFA; C) levels. Participants kept resting for 180 min except when performing each 3 min bout of stair climbing–descending exercise (ST-EX) at 60 and 120 min postmeal (ST-EX session), or kept resting for 180 min (REST session). There were significant interactions between time and intervention on BG (p<0.01) and C peptide (p<0.01), but not NEFA. Values are the mean±SE. **p<0.01 versus corresponding REST. †p<0.05, ††p<0.01 vs 60 min. N=16. Hiroto Honda et al. BMJ Open Diab Res Care 2016;4:e000232 ©2016 by American Diabetes Association